Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Advances clinical research capabilities with leading regulatory grade registries platform
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Subscribe To Our Newsletter & Stay Updated